Co-Diagnostics, Inc. to Present Products and Services at the 2019 AACC Expo August 4-8
August 01 2019 - 6:30AM
Co-Diagnostics, Inc.
(Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that it
will be presenting at the 71st annual AACC Scientific Meeting and
Clinical Lab Expo in Anaheim, California on August 4-8, 2019 and
pursuing sales of Company products and services.
Co-Diagnostics invites all interested parties to
booth #2982, located in Hall C. The Company will use the
opportunity to generate increased interest and sales in its
infectious disease diagnostics vertical, and to introduce and
promote the applications of their CoPrimer™ technology for
next-generation sequencing, liquid biopsy cancer detection, and SNP
differentiation to industry leaders.
The AACC is the world’s largest laboratory
medicine expo, providing opportunities for over 19,000 scientists,
manufacturers and distributors in the IVD and biotech communities
to connect and engage in direct sales of their product offerings.
Expo statistics from participants surveys indicate that 60% of
attendees consider their primary business interest in attending the
AACC to evaluate and acquire lab products or services, 31% of
attendees intend to make a purchase within 1 year, and 58% plan to
do so within 2 years following interactions with AACC
exhibitors.
About Co-Diagnostics,
Inc.:Co-Diagnostics, Inc., a Utah corporation, is a
molecular diagnostics company that develops, manufactures and
markets a new, state-of-the-art diagnostics technology. The
Company’s technology is utilized for tests that are designed using
the detection and/or analysis of nucleic acid molecules (DNA or
RNA). The Company also uses its proprietary technology to design
specific tests to locate genetic markers for use in industries
other than infectious disease and license the use of those tests to
specific customers.
Forward-Looking Statements:
This press release contains
forward-looking statements. Forward-looking statements can be
identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company’s liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company’s products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company’s balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities
laws.
Company Sales
Contact:
Seth
Egan
Head of International
Sales
+1 801-438-1036
#2
s.egan@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024